Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Pulmatrix, Inc. is a biotechnology company focused on developing innovative therapies for respiratory diseases. Its lead product candidate, Pulmazole, targets chronic obstructive pulmonary disease (COPD) and is designed to enhance drug delivery through its proprietary iSPERSE technology, which sets it apart in the crowded respiratory market.
Pulmatrix aims to monetize its proprietary drug delivery technology and product candidates through partnerships with larger pharmaceutical companies, as well as potential direct sales once products are commercialized. The company's competitive advantage lies in its unique delivery system that enhances the efficacy of inhaled therapies, which could lead to better patient outcomes and market acceptance.
Clinical trial results for Pulmazole and other candidates
Partnership announcements with larger pharmaceutical firms
Regulatory approvals from the FDA or EMA
Market adoption rates of its therapies post-launch
Regulatory changes affecting drug approval processes
Technological disruption in drug delivery systems
Emergence of new competitors with similar drug delivery technologies
Potential patent expirations affecting proprietary technology
High cash burn rate with no current revenue generation
Dependence on external funding for continued operations
low - As a biotech firm focused on niche respiratory therapies, Pulmatrix's performance is less sensitive to economic cycles compared to broader healthcare or consumer sectors.
Moderate - Rising interest rates could increase the cost of capital for Pulmatrix, impacting its ability to fund R&D and operations, but the company is currently debt-free.
minimal - The company has no debt, reducing its exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector may be attracted to Pulmatrix's innovative approach.
high - The stock has exhibited significant volatility, as evidenced by its 1-year return of -73.7%.
